Corteria Pharmaceuticals
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload
Inclusion Criteria: * Signed written informed consent * Previous diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required) * Prescribed an oral loop diuretic for at least 1 month preceding the index event * NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL * Requires treatment with i.v. diuretics for volume overload * At least 1 risk factor for diuretic resistance * Admitted to the hospital not more than 120 hours prior to randomization Exclusion Criteria: * Index event primarily triggered by an acute event (e.g. AMI, PE, arrhy…
28-day treatment
28-day treatment